MBP and relapsing-remitting multiple sclerosis: A phase I clinical trial was conducted by Achiron et al. using attenuated T cell lines specific for different MBP and/or MOG peptides.169 The results of the trial showed clinical as well as radiological benefits with no adverse effects in RRMS patients who did not respond to disease-modifying treatments.169 In addition, multivalent TCV allows personalized therapy following prescreening for myelin reactivity.